Merck & Co. Inc.is cancelling development of a Zocor-based combination of its cholesterol product Tredaptive, but the firm is still moving forward with the statin-free combination of niacin and the novel anti-flushing compound laropiprant.
MK-0524B was a combination of the investigational drug Tredaptive (niacin/laropiprant), aka MK-0524A, and Merck’s blockbuster simvastatin, which went off patent in 2006
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?